Drug Trial Radar · NCT07036510
Safety and Efficacy of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery
Last checked: Nov 20, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Jun 12, 2025
Primary completion
Jan 2027
Study completion Jan 2027
Sponsor
- Lead sponsor
- EyeD PharmaIndustry
- Sponsor type
- Industry
- First posted
- Jun 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to test a new method to deliver an approved medicine called Timolol in the eye of participants with glaucoma or ocular hypertension and requiring cataract surgery. The study is conducted in two stages. The first stage (Stage 1/Phase 1) is intended to study the safety of 3 different doses of the study medication (called TimoD implant). The second stage (Stage 2/Phase 2) of the study is intended to study in greater detail the efficacy and safety of the 3 doses of the TimoD implant in comparison to a standard approved medication, timolol eye drops for 3 years.
Conditions
- Glaucoma
- Ocular Hypertension
Interventions
TimoD implantDrug
Consists of 1 TimoD implant administration in the study eye.
Injector systemDevice
This is a CE-marked injector intended for intraocular lens (IOL) delivery. In this study, the injector is used as an"intraocular implant injection system" outside of its scope of intended use.
Timolol eye drops 0.5%Drug
Timolol eye drops will be self-admnistered twice daily in the study eye approximately 12 hours apart throughout the study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stage 1: Number (%) of participants experiencing adverse eventsTime frame: From Screening (up to Day -41) to end of stage 1 (Month 13)
- Stage 1: Number (%) of participants experiencing adverse events of special interest (AESI)Time frame: From Screening (up to Day -41) to end of stage 1 (Month 13)
- Stage 2: Proportion of responders defined as an IOP decrease of 20% or more between baseline and Month 3 (8 AM IOP)Time frame: Month 3
- Stage 2: Proportion of time-matched responders defined as an IOP decrease of 20% or more between baseline and Month 3 (8 AM and 10 AM)Time frame: Month 3
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Panama Eye Center
Panama City, Panama · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.